Skip to main content

Table 4 Comparison of treatment approaches between intestinal BS and mucocutaneous BS

From: Clinical characteristics and risk factors of intestinal involvement in Behçet’s syndrome patients: a cross-sectional study from a single center

Variables Intestinal BS (n = 97, %) Mucocutaneous BS (n = 154, %)
Overall treatment   
Intravenous steroid 97 (100%) 0 (0.00)
Oral steroid 0 (0.00) 29 (18.83)
Sulfasalazine 67 (69.07) 3 (1.95)
Mesalazine 10 (10.31) 0 (0.00)
Colchicine 17 (17.53) 88 (57.14)
Thalidomide 82 (84.54) 143 (92.86)
Total glucosides of paeony capsules 22 (22.68) 108 (70.13)
Hydroxychloroquine 8 (8.25) 21 (13.64)
Cyclosporine 87 (89.69) 79 (51.30)
Biologics 64 (65.98) 4 (2.60)
Number of immunosuppressants used   
0 0 (0) 2 (1.3)
1 2 (2.1) 71 (46.1)
2 8 (8.2) 72 (46.8)
 ≥ 3 87 (89.7) 9 (5.8)